Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06643728
- Locations
- 🇺🇸
Eastside Research Associates, Redmond, Washington, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Central Research Associates, Birmingham, Alabama, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT06635057
- Locations
- 🇸🇦
Al Moosa Hospital, Al Mubarraz, Al-Ahsa, Saudi Arabia
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Bern
- Target Recruit Count
- 42
- Registration Number
- NCT06630585
- Locations
- 🇨🇭
Kantonsspital Olten, Olten, Solothurn, Switzerland
The Effects of Tirzepatide in People with Overweight/obesity and Coronary Artery Disease
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Tina Vilsbøll
- Target Recruit Count
- 124
- Registration Number
- NCT06606821
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Gentofte Hospital, Gentofte, Denmark
🇩🇰Steno Diabetes Center Copenhagen, Herlev, Denmark
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06603571
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇦🇷Centro Médico Viamonte, Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588296
- Locations
- 🇺🇸
Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
🇺🇸Research Physicians Network, LLC, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Katy, Texas, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588283
- Locations
- 🇺🇸
NeoClinical Research, Hialeah, Florida, United States
🇺🇸Skin Care Research, Hollywood, Florida, United States
🇺🇸Encore Medical Research, Hollywood, Florida, United States
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06565611
- Locations
- 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1000
- Registration Number
- NCT06534411
- Locations
- 🇺🇸
Cahaba Research, Pelham, Alabama, United States
🇺🇸Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States
🇺🇸AES Tucson DRS, Tucson, Arizona, United States
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06533527
- Locations
- 🇺🇸
Cleveland Clinic, Weston, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.